Reports Q4 revenue $18.41M vs. $14.2M last year. “With the December approvals of RECELL GO mini and Cohealyx, we have established our position in therapeutic acute wound care,” said Jim Corbett, CEO of Avita Medical (RCEL). “Our expanded portfolio now offers clinicians a suite of advanced technologies optimized for wound healing, effectively accelerating the time to patient recovery. This transformation positions us for long-term growth.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCEL: